NASDAQ:FBRX

Forte Biosciences Competitors

$33.20
-2.57 (-7.18 %)
(As of 04/20/2021 04:30 PM ET)
Add
Compare
Today's Range
$32.37
Now: $33.20
$35.49
50-Day Range
$25.01
MA: $31.08
$39.66
52-Week Range
$13.35
Now: $33.20
$53.99
Volume159,793 shs
Average Volume189,112 shs
Market Capitalization$448.50 million
P/E RatioN/A
Dividend YieldN/A
Beta0.23

Competitors

Forte Biosciences (NASDAQ:FBRX) Vs. RVNC, MGNX, IGMS, KURA, MCRB, and PAND

Should you be buying FBRX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Forte Biosciences, including Revance Therapeutics (RVNC), MacroGenics (MGNX), IGM Biosciences (IGMS), Kura Oncology (KURA), Seres Therapeutics (MCRB), and Pandion Therapeutics (PAND).

Revance Therapeutics (NASDAQ:RVNC) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.

Insider & Institutional Ownership

74.4% of Revance Therapeutics shares are held by institutional investors. Comparatively, 53.0% of Forte Biosciences shares are held by institutional investors. 4.8% of Revance Therapeutics shares are held by company insiders. Comparatively, 10.9% of Forte Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Revance Therapeutics has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500. Comparatively, Forte Biosciences has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500.

Profitability

This table compares Revance Therapeutics and Forte Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Revance Therapeutics-5,818.87%-85.72%-44.85%
Forte BiosciencesN/A-417.87%-248.28%

Valuation & Earnings

This table compares Revance Therapeutics and Forte Biosciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revance Therapeutics$410,000.004,666.01$-159,430,000.00($3.67)-7.30
Forte Biosciences$40,000.0011,212.47$-63,520,000.00($40.33)-0.82

Forte Biosciences has lower revenue, but higher earnings than Revance Therapeutics. Revance Therapeutics is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Revance Therapeutics and Forte Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Revance Therapeutics00403.00
Forte Biosciences00703.00

Revance Therapeutics currently has a consensus price target of $37.75, indicating a potential upside of 41.07%. Forte Biosciences has a consensus price target of $82.00, indicating a potential upside of 145.44%. Given Forte Biosciences' higher possible upside, analysts clearly believe Forte Biosciences is more favorable than Revance Therapeutics.

Summary

Forte Biosciences beats Revance Therapeutics on 7 of the 13 factors compared between the two stocks.

MacroGenics (NASDAQ:MGNX) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership.

Insider and Institutional Ownership

95.8% of MacroGenics shares are owned by institutional investors. Comparatively, 53.0% of Forte Biosciences shares are owned by institutional investors. 9.0% of MacroGenics shares are owned by company insiders. Comparatively, 10.9% of Forte Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility & Risk

MacroGenics has a beta of 2.4, indicating that its share price is 140% more volatile than the S&P 500. Comparatively, Forte Biosciences has a beta of 0.23, indicating that its share price is 77% less volatile than the S&P 500.

Profitability

This table compares MacroGenics and Forte Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MacroGenics-204.31%-65.84%-49.41%
Forte BiosciencesN/A-417.87%-248.28%

Valuation and Earnings

This table compares MacroGenics and Forte Biosciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MacroGenics$64.19 million31.45$-151,810,000.00($3.16)-10.65
Forte Biosciences$40,000.0011,212.47$-63,520,000.00($40.33)-0.82

Forte Biosciences has lower revenue, but higher earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for MacroGenics and Forte Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MacroGenics11902.73
Forte Biosciences00703.00

MacroGenics currently has a consensus price target of $33.40, indicating a potential downside of 0.71%. Forte Biosciences has a consensus price target of $82.00, indicating a potential upside of 145.44%. Given Forte Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Forte Biosciences is more favorable than MacroGenics.

IGM Biosciences (NASDAQ:IGMS) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership.

Valuation and Earnings

This table compares IGM Biosciences and Forte Biosciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IGM BiosciencesN/AN/A$-43,130,000.00($4.80)-12.08
Forte Biosciences$40,000.0011,212.47$-63,520,000.00($40.33)-0.82

IGM Biosciences has higher earnings, but lower revenue than Forte Biosciences. IGM Biosciences is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

47.6% of IGM Biosciences shares are owned by institutional investors. Comparatively, 53.0% of Forte Biosciences shares are owned by institutional investors. 79.3% of IGM Biosciences shares are owned by company insiders. Comparatively, 10.9% of Forte Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares IGM Biosciences and Forte Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IGM BiosciencesN/A-33.30%-30.28%
Forte BiosciencesN/A-417.87%-248.28%

Volatility & Risk

IGM Biosciences has a beta of -1.12, indicating that its share price is 212% less volatile than the S&P 500. Comparatively, Forte Biosciences has a beta of 0.23, indicating that its share price is 77% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for IGM Biosciences and Forte Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IGM Biosciences01602.86
Forte Biosciences00703.00

IGM Biosciences currently has a consensus price target of $98.8750, indicating a potential upside of 70.98%. Forte Biosciences has a consensus price target of $82.00, indicating a potential upside of 145.44%. Given Forte Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Forte Biosciences is more favorable than IGM Biosciences.

Summary

Forte Biosciences beats IGM Biosciences on 7 of the 12 factors compared between the two stocks.

Forte Biosciences (NASDAQ:FBRX) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Valuation & Earnings

This table compares Forte Biosciences and Kura Oncology's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Forte Biosciences$40,000.0011,212.47$-63,520,000.00($40.33)-0.82
Kura OncologyN/AN/A$-63,140,000.00($1.51)-18.51

Kura Oncology has lower revenue, but higher earnings than Forte Biosciences. Kura Oncology is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

53.0% of Forte Biosciences shares are owned by institutional investors. Comparatively, 94.7% of Kura Oncology shares are owned by institutional investors. 10.9% of Forte Biosciences shares are owned by insiders. Comparatively, 11.0% of Kura Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Forte Biosciences and Kura Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Forte BiosciencesN/A-417.87%-248.28%
Kura OncologyN/A-30.96%-28.02%

Volatility and Risk

Forte Biosciences has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 2.15, suggesting that its stock price is 115% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Forte Biosciences and Kura Oncology, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Forte Biosciences00703.00
Kura Oncology011002.91

Forte Biosciences presently has a consensus target price of $82.00, indicating a potential upside of 145.44%. Kura Oncology has a consensus target price of $39.5455, indicating a potential upside of 41.79%. Given Forte Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Forte Biosciences is more favorable than Kura Oncology.

Summary

Kura Oncology beats Forte Biosciences on 8 of the 12 factors compared between the two stocks.

Forte Biosciences (NASDAQ:FBRX) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Valuation & Earnings

This table compares Forte Biosciences and Seres Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Forte Biosciences$40,000.0011,212.47$-63,520,000.00($40.33)-0.82
Seres Therapeutics$34.51 million52.00$-70,280,000.00($1.20)-16.33

Forte Biosciences has higher earnings, but lower revenue than Seres Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

53.0% of Forte Biosciences shares are owned by institutional investors. Comparatively, 94.3% of Seres Therapeutics shares are owned by institutional investors. 10.9% of Forte Biosciences shares are owned by insiders. Comparatively, 4.8% of Seres Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Forte Biosciences and Seres Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Forte BiosciencesN/A-417.87%-248.28%
Seres Therapeutics-385.22%-2,867.98%-51.24%

Volatility and Risk

Forte Biosciences has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 4.07, suggesting that its stock price is 307% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Forte Biosciences and Seres Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Forte Biosciences00703.00
Seres Therapeutics01602.86

Forte Biosciences presently has a consensus target price of $82.00, indicating a potential upside of 145.44%. Seres Therapeutics has a consensus target price of $38.1667, indicating a potential upside of 95.03%. Given Forte Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Forte Biosciences is more favorable than Seres Therapeutics.

Summary

Forte Biosciences beats Seres Therapeutics on 9 of the 14 factors compared between the two stocks.

Forte Biosciences (NASDAQ:FBRX) and Pandion Therapeutics (NASDAQ:PAND) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Valuation & Earnings

This table compares Forte Biosciences and Pandion Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Forte Biosciences$40,000.0011,212.47$-63,520,000.00($40.33)-0.82
Pandion Therapeutics$970,000.001,827.25$-21,880,000.00N/AN/A

Pandion Therapeutics has higher revenue and earnings than Forte Biosciences.

Insider and Institutional Ownership

53.0% of Forte Biosciences shares are owned by institutional investors. Comparatively, 35.7% of Pandion Therapeutics shares are owned by institutional investors. 10.9% of Forte Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Forte Biosciences and Pandion Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Forte BiosciencesN/A-417.87%-248.28%
Pandion TherapeuticsN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and price targets for Forte Biosciences and Pandion Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Forte Biosciences00703.00
Pandion Therapeutics02202.50

Forte Biosciences presently has a consensus target price of $82.00, indicating a potential upside of 145.44%. Pandion Therapeutics has a consensus target price of $44.25, indicating a potential downside of 26.31%. Given Forte Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Forte Biosciences is more favorable than Pandion Therapeutics.

Summary

Forte Biosciences beats Pandion Therapeutics on 6 of the 10 factors compared between the two stocks.


Forte Biosciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$26.80-1.6%$1.91 billion$410,000.00-5.83
MacroGenics logo
MGNX
MacroGenics
1.2$33.66-5.3%$1.91 billion$64.19 million-10.75Analyst Report
Insider Selling
Decrease in Short Interest
News Coverage
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$57.98-1.2%$1.88 billionN/A-24.67Increase in Short Interest
Kura Oncology logo
KURA
Kura Oncology
1.6$27.95-1.2%$1.83 billionN/A-17.15
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$19.60-0.5%$1.80 billion$34.51 million-16.75
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$38.00-0.0%$1.77 billion$14.87 million-14.18Increase in Short Interest
Cytokinetics logo
CYTK
Cytokinetics
1.7$25.30-2.3%$1.77 billion$26.87 million-13.25Analyst Report
News Coverage
MORF
Morphic
1.3$54.26-0.3%$1.76 billion$16.98 million-34.78Decrease in Short Interest
FibroGen logo
FGEN
FibroGen
1.8$20.35-6.6%$1.75 billion$256.58 million-7.80
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.66-0.5%$1.71 billion$428.41 million15.45Analyst Upgrade
News Coverage
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
2.0$5.67-0.2%$1.70 billion$1.63 billion13.83
Generation Bio logo
GBIO
Generation Bio
1.8$30.09-4.1%$1.63 billionN/A0.00
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$17.78-3.5%$1.63 billion$145.97 million-7.20
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.7$30.70-0.8%$1.62 billion$392.76 million12.74Analyst Upgrade
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$17.86-2.1%$1.59 billionN/A-6.36Increase in Short Interest
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$27.42-1.1%$1.54 billionN/A0.00
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$11.87-0.8%$1.52 billion$320,000.00-8.07
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$22.97-4.7%$1.51 billion$2.34 million-9.73
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$25.22-1.6%$1.50 billion$175.34 million-14.84Insider Selling
uniQure logo
QURE
uniQure
1.7$32.51-1.8%$1.49 billion$7.28 million-8.62
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$33.22-5.2%$1.47 billionN/A0.00News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.32-1.2%$1.44 billion$82.27 million-17.85News Coverage
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$22.08-1.0%$1.42 billion$73.41 million-4.67
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$39.76-0.8%$1.41 billionN/A0.00
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$28.66-2.6%$1.40 billionN/A-3.11Analyst Upgrade
News Coverage
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$31.26-0.4%$1.39 billionN/A0.00Increase in Short Interest
OLMA
Olema Pharmaceuticals
1.6$33.55-3.3%$1.39 billionN/A0.00
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$31.89-0.5%$1.39 billion$6.20 million-13.99
Cara Therapeutics logo
CARA
Cara Therapeutics
1.8$27.49-0.5%$1.36 billion$19.89 million-12.97
Endo International logo
ENDP
Endo International
1.5$5.63-4.6%$1.36 billion$2.91 billion-8.28News Coverage
Gap Up
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$26.46-1.7%$1.35 billion$4.23 million-19.60Increase in Short Interest
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$61.25-5.8%$1.34 billionN/A0.00Increase in Short Interest
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$32.15-5.7%$1.28 billionN/A-133.96Gap Up
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$32.29-6.3%$1.26 billionN/A0.00
Zymeworks logo
ZYME
Zymeworks
1.8$26.50-3.7%$1.22 billion$29.54 million-7.03News Coverage
Shattuck Labs logo
STTK
Shattuck Labs
1.5$29.51-1.2%$1.22 billionN/A0.00Analyst Report
Insider Selling
News Coverage
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.8$31.94-3.0%$1.22 billionN/A0.00Analyst Report
Insider Selling
News Coverage
Gap Up
Innoviva logo
INVA
Innoviva
1.4$11.98-0.8%$1.21 billion$261.02 million6.11
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$14.78-3.1%$1.16 billion$4.23 million-8.26
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.01-0.1%$1.16 billion$59.70 million-190.10
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$26.62-2.0%$1.15 billion$230,000.00-12.38
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.11-2.5%$1.14 billionN/A-8.79Increase in Short Interest
News Coverage
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$35.40-2.3%$1.13 billionN/A-2.53
Kronos Bio logo
KRON
Kronos Bio
1.7$20.08-0.1%$1.13 billionN/A0.00
Omeros logo
OMER
Omeros
1.4$18.55-2.5%$1.12 billion$111.81 million-7.79News Coverage
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$31.16-2.0%$1.12 billionN/A-17.31
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$15.90-0.4%$1.10 billion$42.12 million-11.78
NKTX
Nkarta
1.8$31.25-4.0%$1.07 billionN/A0.00
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$16.10-3.9%$1.06 billionN/A-6.79Upcoming Earnings
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.